Sensation modifying topical composition foam
US-9320705-B2 · Apr 26, 2016 · US
US9737561B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9737561-B2 |
| Application number | US-201615353301-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 16, 2016 |
| Priority date | Aug 21, 2009 |
| Publication date | Aug 22, 2017 |
| Grant date | Aug 22, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided according to some embodiments of the invention are topical gels that may release nitric oxide. Also provided are methods of using such topical gels in the treatment of wounds and other skin ailments.
Opening claim text (preview).
We claim: 1. A method of treating a skin ailment in a subject, the method comprising: administering to a subject a topical composition comprising nitric oxide-releasing polysiloxane macromolecules and a hydrophobic, non-aqueous gel base, the hydrophobic, non-aqueous gel base comprising mineral oil, wherein the nitric oxide (NO) storage per gram is in a range of 100 nmol NO/g to 1 mmol NO/g of the topical composition and at least 70% of NO of the nitric oxide-releasing polysiloxane macromolecule remains in the topical composition two days after initial formulation when the topical composition is stored at room temperature. 2. The method of claim 1 , wherein the nitric oxide-releasing polysiloxane macromolecules are diazeniumdiolate-functionalized polysiloxane macromolecules. 3. The method of claim 1 , wherein the method decreases inflammation in the subject. 4. The method of claim 1 , wherein the method decreases inflammatory response factors in the subject. 5. The method of claim 1 , wherein the method modulates inflammatory cytokines in the subject. 6. The method of claim 1 , wherein the skin ailment is an inflammatory skin condition. 7. The method of claim 1 , wherein the skin ailment is impetigo, psoriasis, tinea pedis, or onychomycosis. 8. The method of claim 1 , wherein the topical composition is antimicrobial. 9. The method of claim 1 , wherein the topical composition disperses a biofilm. 10. The method of claim 1 , wherein the topical composition disrupts the structure of the biofilm and/or prevents biofilm formation. 11. The method of claim 1 , wherein the topical composition kills bacteria present in a biofilm. 12. A method of treating a skin ailment in a subject, the method comprising: administering to a subject a topical composition comprising nitric oxide-releasing polysiloxane macromolecules and a hydrophilic gel base, the hydrophilic gel base comprising an alcohol, wherein the nitric oxide (NO) storage per gram is in a range of 100 nmol NO/g to 1 mmol NO/g of the topical composition and at least 70% of NO of the nitric oxide-releasing polysiloxane macromolecule remains in the topical composition two days after initial formulation when the topical composition is stored at room temperature. 13. The method of claim 12 , wherein the nitric oxide-releasing polysiloxane macromolecules are diazeniumdiolate-functionalized polysiloxane macromolecules. 14. The method of claim 12 , wherein the method decreases inflammation in the subject. 15. The method of claim 12 , wherein the method decreases inflammatory response factors in the subject. 16. The method of claim 12 , wherein the method modulates inflammatory cytokines in the subject. 17. The method of claim 12 , wherein the skin ailment is an inflammatory skin condition. 18. The method of claim 12 , wherein the skin ailment is impetigo, psoriasis, tinea pedis, or onychomycosis. 19. The method of claim 12 , wherein the topical composition is antimicrobial. 20. The method of claim 12 , wherein the topical composition disperses a biofilm. 21. The method of claim 12 , wherein the topical composition disrupts the structure of the biofilm and/or prevents biofilm formation. 22. The method of claim 12 , wherein the topical composition kills bacteria present in a biofilm.
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title
Anti-acne agents · CPC title
Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds · CPC title
Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.